GeNeuro's main shareholders

February 2024 – Data presented on a non-diluted basis



Eclosion is a launching platform for new companies in the life sciences field. The company assists entrepreneurs with the necessary resources to cross the bridge between innovation and a realistic venture. Eclosion was a co-founder of GeNeuro in March 2006.


Institut Mérieux Group

Institut Mérieux is a family holding company. This holding company financially supports companies dedicated to the improvement of patient care quality and consumer health throughout the world through innovative biotechnology solutions. It manages a portfolio of 4 main financial investments, including bioMérieux SA, Transgene, ABL Inc and Mérieux Nutrisciences. Institut Mérieux invested in GeNeuro to support the progress of the company.



Servier is an independent French pharmaceutical company, which was GeNeuro’s former development partner in multiple sclerosis. Its development is based on the continuous pursuit of innovation in the therapeutic areas of cardiovascular, metabolic, neurologic, psychiatric, bone and joint diseases as well as cancer. GeNeuro and Servier signed a collaboration agreement in 2014 to develop a medicine addressing a suspected causal factor of multiple sclerosis.